ESMO Preceptorship on NSCLC and SCLC

PROGRAMME

ESMO PRECEPTORSHIP

SINGAPORE 7-8 DECEMBER 2026

CO-CHAIRS

Tony S. K. Mok, Hong Kong SAR, China

Solange Peters, Switzerland

esmo.org

ESMO PRECEPTORSHIP PROGRAMME
NSCLC and SCLC

New standards of care and future perspectives

Singapore
7-8 December 2026

CO-CHAIRS Tony S. K. Mok, Hong Kong SAR, China
Solange Peters, Switzerland

SPEAKERS Lizza Hendriks, Netherlands
Hidehito Horinouchi, Japan
David Planchard, France
Sanjay Popat, United Kingdom
Noemi Reguart, Spain
Jordi Remon Masip, France
Aaron C. Tan, Singapore
Pan-Chyr Yang, Taiwan

LEARNING OBJECTIVES

- To learn about best clinical practice in the management of NSCLC in early, locally advanced and metastatic stages
- To learn about the management of patients with actionable driver alterations and novel targeted agents for advanced NSCLC
- To understand the role of immune checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about the systemic treatment of SCLC and pleural mesothelioma

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This educational programme has been supported by:

AMGEN® AstraZeneca

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano
Switzerland
Email: **courses@esmo.org**
www.esmo.org

ESMO

Monday, 7 December 2026

09:00-09:10 **10'**	**Welcome and introduction**	**Tony S. K. Mok, HK SAR, CN** **Solange Peters, CH**
09:10-10:00 **50'**	**SESSION 1** **Screening**	**Chair:** **Solange Peters, CH**
20'	Screening in Asia	Pan-Chyr Yang, TW
20'	Screening: The smoker-based picture	Lizza Hendriks, NL
10'	Q&A	All
10:00-10:30	Coffee break	
10:30-11:50 **80'**	**SESSION 2** **Advances in the treatment of early-stage lung cancer**	**Chair:** **Tony S. K. Mok, HK SAR, CN**
25'	Perioperative I/O	Solange Peters, CH
20'	Perioperative TKIs	Hidehito Horinouchi, JP
20'	The treatment paradigm for unresectable stage III NSCLC	Lizza Hendriks, NL
15'	Q&A	All
11:50-12:45 **55'**	**SESSION 3** **Advanced-stage lung cancer**	**Chair:** **Tony S. K. Mok, HK SAR, CN**
20'	State-of-the-art in immunotherapy for advanced-stage disease	Noemi Reguart, ES
20'	Addressing resistance with immunotherapy	Solange Peters, CH
15'	Q&A	All
12:45-13:45	Lunch	
13:45-15:10 **85'**	**SESSION 4** **Hitting the target – Part I**	**Chair:** **Solange Peters, CH**
25'	Optimal approach for ADC in NSCLC	David Planchard, FR
20'	What is new about EGFR mutations?	Tony S. K. Mok, HK SAR, CN
25'	What about fusions?	Jordi Remon Masip, FR
15'	Q&A	All
15:10-15:40	Coffee break	
15:40-16:35 **55'**	**SESSION 5** **Hitting the target – Part II**	**Chair:** **Tony S. K. Mok, HK SAR, CN**
25'	Additional actionable mutations	Aaron C. Tan, SG
20'	Can we conquer KRAS mutations?	Tony S. K. Mok, HK SAR, CN
10'	Q&A	All
16:35-17:50 **75'**	**SESSION 6** **Participants clinical case discussion**	**Chair:** **Solange Peters, CH**
75'	Participants clinical case discussion (5x15') NSCLC x 2 cases / SCLC x 3 cases	Faculty
18:00	Networking cocktail	

Tuesday, 8 December 2026

09:00-10:30 90’	SESSION 7 Novel approach to SCLC – Part I	Chair: Tony S. K. Mok, HK SAR, CN
25’	Standard of care management of limited-stage SCLC	David Planchard, FR
25’	Frontline standard of care management of extensive-stage SCLC (excluding TCE and ADCs)	Noemi Reguart, ES
25’	Second-line strategies for extensive-stage SCLC (excluding TCE and ADCs)	Aaron C. Tan, SG
15’	Q&A	All
10:30-11:00	Coffee break	
11:00-12:30 90’	SESSION 8 Novel approach to SCLC – Part II	Chair: Solange Peters, CH
25’	T-cell engagers for SCLC	Sanjay Popat, UK
25’	Perspectives in drug development in SCLC (ADCs, bispecifics)	Hidehito Horinouchi, JP
25’	Areas of controversy in SCLC: PCI, PS2, biomarkers, treatment sequence	Jordi Remon Masip, FR
15’	Q&A	All
12:30-12:40 10’	Conclusion and farewell	Tony S. K. Mok, HK SAR, CN Solange Peters, CH
12:40-13:40	Lunch	

Note: Each 15-min slot for clinical case discussion includes a 7’ case presentation and an 8’ Q&A / interactive panel discussion